此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

利用机器学习和人工智能算法优化急性透析的性能与实施 (SMART DIALYSIS)

2026年9月22日 更新者:University of Alberta

SMART DIALYSIS - 扩展机器学习和人工智能算法以优化急性透析的性能与实施。

SMART DIALYSIS - Scaling Machine Learning and Artificial Intelligence AlgoRithms to OpTimize the Performance and Delivery of Acute DIALYSIS.

Hypothesis:

Can the investigators develop and implement Machine Learning and Artificial Intelligence Algorithms into Clinical Information Systems to Optimize the Prescription, Delivery, and Performance of Acute Dialysis?

Objective(s):

  1. Identify variables surrounding identified Key Performance Indicators that may be used by Machine Learning and Artificial Intelligence algorithms to optimize the prescription and performance of acute dialysis.
  2. Develop Machine Learning and Artificial Intelligence algorithms to help guide the prescription and delivery of acute dialysis in the development of Clinical Decision Support tools and Best Practice Advisories and create a ML/AI Augmented SMART DIALYSIS Digital Dashboard.
  3. Implement and evaluate the performance of the developed Machine Learning and Artificial Intelligence algorithms on patient-centered and health economic outcomes.
  4. Validate and benchmark the performance of the evaluated Machine Learning and Artificial Intelligence algorithms across multiple jurisdictions.

研究概览

详细说明

Study Background & Rationale:

Acute dialysis is required in approximately 10-15% of all patients admitted to intensive care units (ICUs). Acute dialysis may take the form of continuous renal replacement therapy (CRRT), intermittent hemodialysis (IHD) or slow-low efficiency dialysis (SLED). Worldwide, CRRT remains the predominant form of acute dialysis, with over 75% of acute dialysis being CRRT.

The application of acute dialysis in the ICU is associated with poor patient outcomes. Despite advances in medical technology and care, mortality remains between 40-60%, which is similar to outcomes observed with severe acute respiratory distress syndrome (ARDS). Additionally, even when patients survive their critical illness, up to 10% of patients require ongoing long-term chronic dialysis therapy. This has a significant effect on the quality of life of survivors of critical illness, as well as important effects on their families, often requiring changes in work and housing status, as well as relocation to sites in closer proximity to dialysis centres. This results in not only significant healthcare and social costs (approximately $100,000/patient/year in Alberta, Canada), but also very important reductions in the health-related quality of lives for these patients. Currently, while evidence exist regarding the optimal initiation of acute dialysis, there is a paucity of evidence to predict timing of modality transition or liberation from this therapy. Using a completely integrated electronic Clinical Information System (eCIS) such as Connect Care (EPIC, Wisconsin, USA) in Alberta, the investigators can develop predictive algorithms that may anticipate patient and acute dialysis needs.

Once, acute dialysis is initiated, several factors may affect kidney recovery following acute dialysis. Intra-dialytic hypotension has been identified as a leading modifiable factor, but unfortunately, one where clinicians have limited capacity to accurately predict. This is an important knowledge gap that must be addressed. It has also been previously identified by our study team as one of the most important key performance indicators (KPI) for acute dialysis, especially in IHD and SLED. For CRRT, filter life has been identified as the most important and studied KPI. Both of these KPIs are currently being utilized by the ongoing QUALITY CRRT and DIALYZING WISELY programs to improve the performance and delivery of acute dialysis to critically ill patients. These two programs have been successfully implemented across Alberta and have established the infrastructure necessary to initiate the next steps in these Continuous Quality Initiatives for acute dialysis, the SMART DIALYSIS program.

Recently, advances in computer and machine processing have led to the 4th industrial revolution featuring the development of smart machines, devices, and learning algorithms that can aid humans in the management of patients and optimize the delivery of healthcare. Machine Learning (ML) and Artificial Intelligence (AI) algorithms have been previously used in medicine, but have only begun their implementation into critical care nephrology.

Current initiatives are primarily focused on pattern recognition and risk prediction. This program will contain 4 distinct phases.

In Phase 1, the investigators will continue work from our QUALITY CRRT and DIALYZING WISELY program and will aim to better understand the landscape surrounding decisions around transitions between acute dialysis modalities, termination, and attempts at liberation from acute dialysis, the incidence of intra-dialytic hypotension, and timing of filter clotting in the ICU.

In Phase 2, the investigators will develop models and subsequent Clinical Decision Support (CDS) tools and/or Best Practice Advisories (BPAs) for clinicians to better predict and manage 1) transitions between acute dialysis therapies, 2) management of intra-dialytic hypotension, 3) prediction of filter life and 4) liberation from acute dialysis. Concurrent with this work, we will work to develop an AI/ML Augmented Acute Dialysis Dashboard (i.e., SMART DIALYSIS Digital Dashboard) embedded within our electronic Clinical Information System (eCIS) to present these KPIs to clinicians.

Phase 3 will look into implementing and evaluating the performance and acceptability of these ML/AI algorithms in clinical practice.

Finally, Phase 4 will take our Alberta-derived results and look to implement and benchmark these across other large healthcare authorities to ensure that the algorithms have been developed and validated appropriately and ethically. These will include partners across Canada, the US, Europe and Australia and New Zealand.

研究类型

观察性的

注册 (估计的)

7500

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Oleksa G Rewa, MD MSc FRCPC
  • 电话号码:17802633280
  • 邮箱:rewa@ualberta.ca

研究联系人备份

学习地点

    • Alberta
      • Calgary、Alberta、加拿大、T2N 2T9
        • Foothills Medical Center
        • 接触:
      • Calgary、Alberta、加拿大、T1Y 6J4
        • Peter Lougheed Center
        • 接触:
      • Calgary、Alberta、加拿大、T2V 1P9
        • Rockyview General Hospital
        • 接触:
      • Calgary、Alberta、加拿大、T3M 1M4
        • South Health Campus
        • 接触:
      • Edmonton、Alberta、加拿大、T5H 3V9
        • Royal Alexandra Hospital
        • 接触:
      • Edmonton、Alberta、加拿大、T6L 5X8
        • Grey Nuns Community Hospital
        • 接触:
      • Edmonton、Alberta、加拿大、T6G-2B7
        • University of Alberta Hospital
        • 接触:
      • Edmonton、Alberta、加拿大、T5R 4H5
        • Misericordia Community Hospital
        • 接触:
      • Edmonton、Alberta、加拿大、T6G-2B7
        • Mazankowski Heart Institute
        • 接触:
      • Fort McMurray、Alberta、加拿大、T9H 1P2
        • Northern Lights Regional Hospital.
        • 接触:
      • Grand Prairie、Alberta、加拿大、T8V 4B1
        • Grand Prairie Regional Hospital
        • 接触:
      • Lethbridge、Alberta、加拿大、T1J 1W5
        • Chinook Regional Hospital
        • 接触:
      • Medicine Hat、Alberta、加拿大、T1A 4H6
        • Medicine Hat Regional Hospital
        • 接触:
      • Red Deer、Alberta、加拿大、T4N 4E7
        • Red Deer Regional Hospital
        • 接触:
      • St. Albert、Alberta、加拿大、T8N 6C4
        • Sturgeon Community Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

The study population will comprise critically ill patients admitted to an intensive care unit who require acute renal replacement therapy.

描述

Inclusion Criteria

Patients admitted to an intensive care unit (ICU) who require acute renal replacement therapy, either intermittent or continuous.

Exclusion Criteria

Receipt of renal replacement therapy for less than 24 hours.

Pre-existing end-stage kidney disease.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Critically ill patients requiring acute dialysis

Admitted to an intensive care unit; requiring acute dialysis

We will include any critically ill patient admitted to an intensive care unit requiring acute dialysis.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Identify Key Performance Indicators that may be used by Machine Learning algorithms.
大体时间:12 month

Key Performance Indicators

12 month
Develop Artificial Intelligence and Machine Learning algorithms
大体时间:36 month

Artificial Intelligence and Machine Learning algorithms

36 month
Evaluate the performance of the developed Artificial Intelligence and Machine Learning algorithms.
大体时间:60 month

ICU and hospital mortality; Renal Recovery at ICU and hospital discharge and 90 days; ICU and hospital lengths of stay; Hospital Costs

60 month

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Oleksa G Rewa, MD MSc、University of Alberta

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2030年6月30日

研究完成 (估计的)

2031年6月30日

研究注册日期

首次提交

2025年12月17日

首先提交符合 QC 标准的

2025年12月17日

首次发布 (实际的)

2025年12月31日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅